Dr. Daisuke Tomizawa is a pediatric hematologist/oncologist and Head of the Division of Leukemia and Lymphoma at the Children's Cancer Center, National Center for Child Health and Development in Tokyo, Japan. He served as Vice Chair of the Japan Children's Cancer Group (JCCG) acute myeloid leukemia (AML) disease committee from 2010-2019 and Chair from 2019-2023, which is responsible for the design and conduct of clinical trials and linked translational research studies that enroll approximately 80% of Japanese children and adolescents with this disease. He is also involved in various international research projects in collaboration with North American, Western European, and Asian investigators in this field.Dr. Edward Anders Kolb is a pediatric hematologist/oncologist, and most recently served as Chief of the Division of Hematology and Oncology of Nemours Children’s Health, Wilmington, Delaware, and Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb also served as Chair of the Children’s Oncology Group (COG) Myeloid Disease Committee from 2013-2023, which is the largest pediatric AML research consortium in the world. He is a strong advocate for international collaboration and leads the development of several international clinical trials. Since 2023, Dr. Kolb was appointed as President and Chief Executive Officer, The Leukemia & Lymphoma Society (LLS) in its mission to cure blood cancers and improve the quality of life for patients and their families.Prof. Dr. Dirk Reinhardt is a pediatric hematologist/oncologist and Head of Pediatrics III, Pediatric Hematology, Oncology and Stem Cell Therapy at the University Children's Hospital Essen, Germany. He is chairman of the AML-BFM study group, which conducts clinical trials as well as basic and translational research on pediatric AML. As Managing Director of the German Society for Pediatric Oncology and Hematology (GPOH gGmbH) and Director of the EuPAL Foundation, he promotes international projects in drug and therapy development for the treatment of cancer and leukemia in children.

• Part-1: Epidemiology and Biology of Pediatric AML. Overview and Epidemiology of Pediatric AML.-  Chromosomal and Genomic Alterations in Pediatric AML.-  Germline Predisposition of Pediatric AML. Part-2: Diagnosis of pediatric AML. Diagnosis and Classifications of Pediatric AML.-  Measurable Residual Disease Assessment in Pediatric AML. Part-3: Advances in Treatment of Pediatric AML. De Novo AML.-  Extramedullary AML (CNS disease. non-CNS extramedullary disease. and myeloid sarcoma).-  Acute Promyelocytic Leukemia.-  Myeloid Proliferations Associated with Down Syndrome (ML-DS. TAM).-  Myeloproliferative Disorders in Non-Down Syndrome Patients.-  AML in Specific Age Groups (Infants. Adolescents and Young Adults).-  Myeloid Neoplasms Post Cytotoxic Therapy in Children.-  Advanced MDS in Children.-  Relapsed/Refractory AML in Children and Evolution of Novel Therapies.-  Stem Cell Transplantation/Cellular and Immunotherapies.-  Pediatric AML in Resource-Limited Countries. Part-4: Supportive Issues in Pediatric AML. Infection Management in Pediatric AML.-  Cardiotoxicity in Pediatric AML.-  Late effects in Pediatric AML Survivors.

Dr. Daisuke Tomizawa is a pediatric hematologist/oncologist and Head of the Division of Leukemia and Lymphoma at the Children's Cancer Center, National Center for Child Health and Development in Tokyo, Japan. He served as Vice Chair of the Japan Children's Cancer Group (JCCG) acute myeloid leukemia (AML) disease committee from 2010-2019 and Chair from 2019-2023, which is responsible for the design and conduct of clinical trials and linked translational research studies that enroll approximately 80% of Japanese children and adolescents with this disease. He is also involved in various international research projects in collaboration with North American, Western European, and Asian investigators in this field.Dr. Edward Anders Kolb is a pediatric hematologist/oncologist, and most recently served as Chief of the Division of Hematology and Oncology of Nemours Children’s Health, Wilmington, Delaware, and Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb also served as Chair of the Children’s Oncology Group (COG) Myeloid Disease Committee from 2013-2023, which is the largest pediatric AML research consortium in the world. He is a strong advocate for international collaboration and leads the development of several international clinical trials. Since 2023, Dr. Kolb was appointed as President and Chief Executive Officer, The Leukemia & Lymphoma Society (LLS) in its mission to cure blood cancers and improve the quality of life for patients and their families.Prof. Dr. Dirk Reinhardt is a pediatric hematologist/oncologist and Head of Pediatrics III, Pediatric Hematology, Oncology and Stem Cell Therapy at the University Children's Hospital Essen, Germany. He is chairman of the AML-BFM study group, which conducts clinical trials as well as basic and translational research on pediatric AML. As Managing Director of the German Society for Pediatric Oncology and Hematology (GPOH gGmbH) and Director of the EuPAL Foundation, he promotes international projects in drug and therapy development for the treatment of cancer and leukemia in children.

• Part-1: Epidemiology and Biology of Pediatric AML. Overview and Epidemiology of Pediatric AML.-  Chromosomal and Genomic Alterations in Pediatric AML.-  Germline Predisposition of Pediatric AML. Part-2: Diagnosis of pediatric AML. Diagnosis and Classifications of Pediatric AML.-  Measurable Residual Disease Assessment in Pediatric AML. Part-3: Advances in Treatment of Pediatric AML. De Novo AML.-  Extramedullary AML (CNS disease. non-CNS extramedullary disease. and myeloid sarcoma).-  Acute Promyelocytic Leukemia.-  Myeloid Proliferations Associated with Down Syndrome (ML-DS. TAM).-  Myeloproliferative Disorders in Non-Down Syndrome Patients.-  AML in Specific Age Groups (Infants. Adolescents and Young Adults).-  Myeloid Neoplasms Post Cytotoxic Therapy in Children.-  Advanced MDS in Children.-  Relapsed/Refractory AML in Children and Evolution of Novel Therapies.-  Stem Cell Transplantation/Cellular and Immunotherapies.-  Pediatric AML in Resource-Limited Countries. Part-4: Supportive Issues in Pediatric AML. Infection Management in Pediatric AML.-  Cardiotoxicity in Pediatric AML.-  Late effects in Pediatric AML Survivors.

Dr. Daisuke Tomizawa is a pediatric hematologist/oncologist and Head of the Division of Leukemia and Lymphoma at the Children's Cancer Center, National Center for Child Health and Development in Tokyo, Japan. He served as Vice Chair of the Japan Children's Cancer Group (JCCG) acute myeloid leukemia (AML) disease committee from 2010-2019 and Chair from 2019-2023, which is responsible for the design and conduct of clinical trials and linked translational research studies that enroll approximately 80% of Japanese children and adolescents with this disease. He is also involved in various international research projects in collaboration with North American, Western European, and Asian investigators in this field.Dr. Edward Anders Kolb is a pediatric hematologist/oncologist, and most recently served as Chief of the Division of Hematology and Oncology of Nemours Children’s Health, Wilmington, Delaware, and Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb also served as Chair of the Children’s Oncology Group (COG) Myeloid Disease Committee from 2013-2023, which is the largest pediatric AML research consortium in the world. He is a strong advocate for international collaboration and leads the development of several international clinical trials. Since 2023, Dr. Kolb was appointed as President and Chief Executive Officer, The Leukemia & Lymphoma Society (LLS) in its mission to cure blood cancers and improve the quality of life for patients and their families.Prof. Dr. Dirk Reinhardt is a pediatric hematologist/oncologist and Head of Pediatrics III, Pediatric Hematology, Oncology and Stem Cell Therapy at the University Children's Hospital Essen, Germany. He is chairman of the AML-BFM study group, which conducts clinical trials as well as basic and translational research on pediatric AML. As Managing Director of the German Society for Pediatric Oncology and Hematology (GPOH gGmbH) and Director of the EuPAL Foundation, he promotes international projects in drug and therapy development for the treatment of cancer and leukemia in children.

• Part-1: Epidemiology and Biology of Pediatric AML. Overview and Epidemiology of Pediatric AML.-  Chromosomal and Genomic Alterations in Pediatric AML.-  Germline Predisposition of Pediatric AML. Part-2: Diagnosis of pediatric AML. Diagnosis and Classifications of Pediatric AML.-  Measurable Residual Disease Assessment in Pediatric AML. Part-3: Advances in Treatment of Pediatric AML. De Novo AML.-  Extramedullary AML (CNS disease. non-CNS extramedullary disease. and myeloid sarcoma).-  Acute Promyelocytic Leukemia.-  Myeloid Proliferations Associated with Down Syndrome (ML-DS. TAM).-  Myeloproliferative Disorders in Non-Down Syndrome Patients.-  AML in Specific Age Groups (Infants. Adolescents and Young Adults).-  Myeloid Neoplasms Post Cytotoxic Therapy in Children.-  Advanced MDS in Children.-  Relapsed/Refractory AML in Children and Evolution of Novel Therapies.-  Stem Cell Transplantation/Cellular and Immunotherapies.-  Pediatric AML in Resource-Limited Countries. Part-4: Supportive Issues in Pediatric AML. Infection Management in Pediatric AML.-  Cardiotoxicity in Pediatric AML.-  Late effects in Pediatric AML Survivors.